PPCov-19: Prevalence of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region

Sponsor
Universidad de Magallanes (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05855382
Collaborator
Centro Asistencial Docente e Investigación de la Universidad Magallanes (CADI-UMAG) (Other), University of Chile (Other), Universidad de Santiago de Chile (Other)
282
1
7
40.1

Study Details

Study Description

Brief Summary

This cross-sectional observational study aims to determine the prevalence of Persistent COVID-19 in 282 individuals in Punta Arenas, Magallanes and Chilean Antarctic Region. Persistent COVID-19 is a complex array of symptoms that persist or emerge for more than 4 weeks beyond SARS-CoV-2 infection. Recent studies suggest that up to 80% of survivors may develop chronic multi-organ dysfunction due to persistent inflammation and immune dysregulation, making it an ongoing public health concern worldwide.

The study aims to (1) describe and establish the frequency of physical and psychological signs and symptoms in adult patients who have tested positive for COVID-19, (2) identify individuals who meet the WHO case definition of Persistent COVID-19 in Chile, (3) explore risk factors associated with persistent COVID-19 to guide intervention strategies, and (4) explore inflammatory and molecular biomarkers associated with persistent COVID-19.

The research project utilizes a stratified random sampling with a mixed-methods embedded design. In the first phase, individuals diagnosed with COVID-19 will be recruited and followed up to complete the study's sample universe. A sociodemographic survey, blood sampling (including complete blood count, biochemical profile, immunoglobulin mutational status analysis, and analysis of inflammatory biomarkers), and a battery of psychological tests will be administered. In the second phase, kinesiology studies and medical consultation and evaluation will be conducted to determine if individuals have Persistent COVID-19 and to derive them to the healthcare network. In the final follow-up phase, participants diagnosed with Persistent COVID-19 will be invited to undergo musculoskeletal and respiratory assessments to complete the diagnosis of symptoms associated with the pathology.

Condition or Disease Intervention/Treatment Phase
  • Other: Persistent COVID-19

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
282 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
A Prevalence Study of Persistent COVID-19 in Punta Arenas, Magallanes and Chilean Antarctic Region
Anticipated Study Start Date :
May 15, 2023
Anticipated Primary Completion Date :
Oct 15, 2023
Anticipated Study Completion Date :
Dec 15, 2023

Arms and Interventions

Arm Intervention/Treatment
COVID-19

Adults with at least one positive SARS-CoV-2 RT-qPCR test

Other: Persistent COVID-19
To determine the prevalence of persistent COVID-19 diagnosis in the current study, we will identify adults between 18 and 100 years of age who have had at least one positive SARS-CoV-2 RT-qPCR test from the COVID-19 database maintained by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.

Outcome Measures

Primary Outcome Measures

  1. To determine the prevalence of persistent COVID-19 in a cohort of patients in Punta Arenas [13 months]

Secondary Outcome Measures

  1. Sociodemographic data questionnaire [3 months]

    to determine the number of prior illnesses, medical treatments, and vaccination records, as well as the quality of life scales, persistent COVID-19 symptoms through self-reported survey data, and Informed Consent Comprehension Questionnaire.

  2. Psychological profiles [3 months]

    Beck Anxiety Scale (BAI)

  3. Psychological profiles [3 months]

    D2-R test of attention

  4. Psychological profiles [3 months]

    Wechsler Adult Intelligence Scale (WAIS)

  5. Sleep quality and disorders [3 months]

    Pittsburgh Sleep Quality Index (PSQI)

  6. Psychosocial exposures [3 months]

    COVID-19 related stress questionnaire based on the Perceived Stress Scale

  7. Psychosocial exposures [3 months]

    Normal activities and work productivity questionnaire; daily diaries

  8. Standard laboratory parameters [3 months]

    Full blood count

  9. Standard laboratory parameters [3 months]

    Serum chemistry test

  10. Inflammatory Biomarkers [6 months]

    Interleukin-8 (IL-8)

  11. Inflammatory Biomarkers [6 months]

    Interleukin-1β (IL-1β)

  12. Inflammatory Biomarkers [6 months]

    Interleukin-6 (IL-6)

  13. Inflammatory Biomarkers [6 months]

    Interleukin-10 (IL-10)

  14. Inflammatory Biomarkers [6 months]

    Tumor Necrosis Factor (TNF)

  15. Inflammatory Biomarkers [6 months]

    Interleukin-12 (IL-12p70)

  16. Immunological repertoire associated with persistent COVID-19 [6 months]

    DNA sequencing results

  17. Flow Cytometry Immunophenotyping [6 months]

    Quantify different lymphocyte subpopulations in persistent COVID-19

  18. Flow Cytometry Immunophenotyping [6 months]

    Quantify Age-Associated B Cells and Their Potential Role in Persistent COVID-19 Pathogenesis

  19. Function of the musculoskeletal system [6 months]

    Fatigue Assessment Scale (FAS)

  20. Function of the musculoskeletal system [6 months]

    Body Composition Analysis Assessment

  21. Function of the musculoskeletal system [6 months]

    Hand Grip Strength Test

  22. Function of the musculoskeletal system [6 months]

    Maximum inspiratory pressure test (MIP test)

  23. Diagnosis of prevalent COVID-19 [8 months]

    Clinical determination of whether the patient has persistent COVID-19 or not is necessary for referral to the appropriate healthcare system

Other Outcome Measures

  1. Musculoskeletal Capacity [2 months]

    Heart Rate Variability (HRV) analysis

  2. Musculoskeletal Capacity [2 months]

    walk test (distance): 3D temporal scanning system for gait analysis by photogrammetry

  3. Musculoskeletal Capacity [2 months]

    Postural Stability and Control Assessment Using Balance Tests

  4. Respiratory function: [2 months]

    Spirometry: measurement of respiratory flows and volumes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥ 18 years

  • Individuals must be included in the COVID-19 monitoring database by the SEREMI of Health in Punta Arenas between July 2022 and July 2023.

  • Patients able to give informed consent.

Exclusion Criteria:
  • Age < 18 years

  • Any physical, mental, immunosuppressive, or social condition that, in the investigator's judgment, might interfere with the completion of the baseline assessments and evaluations.

  • Individuals who are digitally illiterate and do not have access to nearby networks to support them during the process.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Teaching and Research Healthcare Center of the University of Magallanes (CADI-UMAG) Punta Arenas Magllanes And Chilean Antartic Region Chile 6200000

Sponsors and Collaborators

  • Universidad de Magallanes
  • Centro Asistencial Docente e Investigación de la Universidad Magallanes (CADI-UMAG)
  • University of Chile
  • Universidad de Santiago de Chile

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Marcelo A. Navarrete Signorile, Principal Investigator, Universidad de Magallanes
ClinicalTrials.gov Identifier:
NCT05855382
Other Study ID Numbers:
  • FIC-R 40036196-0
First Posted:
May 11, 2023
Last Update Posted:
May 11, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 11, 2023